RCKT Insider Trading Activity and SEC Form 4 Filings
RCKT insider trading summary
Over the past 12 months, insiders at Rocket Pharmaceuticals, Inc. (RCKT) reported 25 sales worth $864K by 6 insiders and 1 open-market purchase worth $34K by 1 insider on SEC Form 4. Net insider selling was $830K.
Latest RCKT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Martin Wilson | General Counsel | Sell | $256K (75,364 @ $3.40) |
| Aug 18, 2026 | Martin Wilson | General Counsel | Sell | $2K (631 @ $3.38) |
| Aug 18, 2026 | Gaurav Shah | CEO | Sell | $8K (2,293 @ $3.38) |
| Aug 13, 2026 | Martin Wilson | General Counsel | Sell | $12K (3,493 @ $3.38) |
| Aug 13, 2026 | Gaurav Shah | CEO | Sell | $10K (2,837 @ $3.38) |
| Aug 11, 2026 | Christopher James Stevens | Chief Operating Officer | Sell | $128K (36,658 @ $3.50) |
| Aug 11, 2026 | Sarbani Chaudhuri | See Remarks | Sell | $16K (4,701 @ $3.50) |
| May 21, 2026 | Gaurav Shah | CEO | Sell | $172K (55,684 @ $3.09) |
| May 19, 2026 | John Militello | See Remarks | Sell | $1K (384 @ $3.01) |
| May 19, 2026 | Martin Wilson | General Counsel | Sell | $2K (662 @ $3.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.